Back to top
more

Alpine Immune Sciences (ALPN)

(Real Time Quote from BATS)

$64.62 USD

64.62
1,539,642

+0.05 (0.08%)

Updated Apr 25, 2024 03:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex

by Zacks Equity Research

Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.

Alpine Immune Sciences (ALPN) Moves 10.4% Higher: Will This Strength Last?

by Zacks Equity Research

Alpine Immune Sciences (ALPN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Lyra Therapeutics (LYRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Alpine Immune Sciences, Inc. (ALPN) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of 146.88% and 346.89%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

StoneCo (STNE) to Post Q4 Earnings: What's in the Offing?

by Zacks Equity Research

StoneCo's (STNE) fourth-quarter 2023 performance will likely reflect strength in its financial services and software business.

Is a Surprise Coming for Alpine Immune Sciences (ALPN) This Earnings Season?

by Zacks Equity Research

Alpine Immune Sciences (ALPN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Will Revenue Decline Impact Jabil's (JBL) Q2 Earnings?

by Zacks Equity Research

Jabil (JBL) is expected to report a top-line contraction year over year in the second quarter of fiscal 2024, owing to soft demand trends in several business segments.

Adobe (ADBE) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Adobe's (ADBE) first-quarter fiscal 2024 results are expected to reflect gains from the solid momentum across the Digital Media and Digital Experience segments.

Alpine Immune Sciences, Inc. (ALPN) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Alpine Immune Sciences, Inc. (ALPN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SentinelOne (S) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

SentinelOne's (S) fourth-quarter fiscal 2024 performance is expected to have benefited from its robust growth in the Singularity platform.

Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 13.04% and 11.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Is Cybin Inc. (CYBN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Cybin Inc. (CYBN) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.

Is Alpine Immune Sciences (ALPN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Alpine Immune Sciences, Inc. (ALPN) and Corbus Pharmaceuticals (CRBP) have performed compared to their sector so far this year.

Is it a Good Idea to Buy Journey Medical (DERM) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in Journey Medical (DERM) stock now may turn out to be a prudent move.

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical

by Zacks Equity Research

Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical are part of the Zacks Industry Outlook article.

Kinjel Shah headshot

5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year

by Kinjel Shah

Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.

Wall Street Analysts See a 56.25% Upside in Alpine Immune Sciences, Inc. (ALPN): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Alpine Immune Sciences, Inc. (ALPN) points to a 56.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Is Alpine Immune Sciences (ALPN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Alpine Immune Sciences, Inc. (ALPN) and Novo Nordisk (NVO) have performed compared to their sector so far this year.

Wall Street Analysts Think Alpine Immune Sciences, Inc. (ALPN) Could Surge 79.37%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 79.4% in Alpine Immune Sciences, Inc. (ALPN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Alcon (ALC) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.

Alpine Immune Sciences, Inc. (ALPN) Surges 8.9%: Is This an Indication of Further Gains?

by Zacks Equity Research

Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Are Medical Stocks Lagging Alcon (ALC) This Year?

by Zacks Equity Research

Here is how Alcon (ALC) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.

Alpine Immune Sciences, Inc. (ALPN) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Alpine Immune Sciences, Inc. (ALPN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

New Strong Buy Stocks for October 23rd

by Zacks Equity Research

MNTX, IPA, AHT, VCEL and ALPN have been added to the Zacks Rank #1 (Strong Buy) List on October 23, 2023.

Is it a Good Idea to Invest in Dynavax (DVAX) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in Dynavax Technologies (DVAX) stock now may turn out to be a prudent move.